



World Health  
Organization

## INTERSESSIONAL CHANGES

# THE INTERAGENCY EMERGENCY HEALTH KIT 2017

Medicines and medical devices  
for 10 000 people for approximately three months



ICRC



International Federation  
of Red Cross and Red Crescent Societies



MEDECINS  
SANS FRONTIERES



UNFPA



UNHCR  
The UN Refugee Agency

unicef 

## Inter-sessional change in the: Supplementary module - Post-exposure prophylaxis (PEP) – Effective Jan 2021

### Background

WHO updated the recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis (PEP) in December 2018. These changes affect the IEHK 2017- PEP module content. This inter-sessional change is proposed to support the changes and avoid inconsistency. **All** other modules of the IEHK2017 remain the same. **Only the PEP module has been changed.**

### Changes

To align with the WHO HIV recommendations, changes in ARV treatments were made for both adults and children:

- **Adults:** use of the 3 FDC: Lamivudine (3TC) + Tenofovir (TDF)+ Dolutegravir (DTG), 300mg+300mg+50mg
- **Children:** backbone regimen selected - Abacavir (ABC) + Lamivudine (3TC) 120 + 60 mg  
With third drug – Dolutegravir (DTG) 50mg or 10mg dispersible tablets (according to the weight)
- **Children below 20 kg:** as Dolutegravir (DTG) 10mg dispersible is under pre-qualification and might not be available until Q3,2021, Lopinavir/ritonavir (LPV/r) 120mg +25mg tablets or 40+10 mg granules or pellets will remain an alternative for children below 20kg.
- **Ratio of children : 9 weighing 20-35 kg: 1 below 20 kg**

Changes are only affecting the ARV treatments, no other changes were made in that module.

**Supplementary module – Intersessional Post-exposure prophylaxis (PEP) 2021 content**  
(to align with WHO guidelines, all ARV drugs have been changed , see in red)

PEP unit, 50 treatments adults + 10 children <sup>1</sup>		
Item description	Unit	Quantity
Azithromycin, powder for oral suspension, 200 mg /5 ml	bottle, 15-30 ml	10
Azithromycin, 250 mg (or 500mg)	tablet/capsule (scored tablet)	200 (100)
Cefixime (as trihydrate), powder for oral suspension, 100 mg/5 ml <sup>2</sup>	bottle, 50 ml	10
Cefixime, tablets 200 mg <sup>3</sup>	tablet	112
Lamivudine (3TC) + Tenofovir (TDF)+ Dolutegravir (DTG), 300mg+300mg+50mg	tablet	1500
Abacavir (ABC) + Lamivudine (3TC) 120 + 60 mg	Dispersible Tablet	870
Dolutegravir DTG 50 mg	tablet	270
Dolutegravir DTG 10 mg <sup>4</sup>	Dispersible Tablet	60
Levonorgestrel, tablets 1.50 mcg	tablet	50
Pregnancy test, (urine dipstick)	unit	50
Flash Drive with full set of guidance documents	unit	1

- 1 10 children: **9** children between 20 and 35 kg and **1** child < 20kg
- 2 Can be replaced with cefixime dispersible tablets.
- 3 Could be interchanged with 400 mg scored tablet.
- 4 **If DGT 10mg sourcing is challenging**, LPV/r 120mg+25mg tablets or 40/10 mg granules or pellets will remain an alternative for children below 20kg. **See below dosage table per kg** (vis Annex 3: dosages for ARV drugs [https://www.who.int/hiv/pub/guidelines/ARV\\_Guidelines-2018-Annex3a.pdf?ua=1](https://www.who.int/hiv/pub/guidelines/ARV_Guidelines-2018-Annex3a.pdf?ua=1))

**Table 3 Simplified dosing of child-friendly solid and oral liquid formulations for twice-daily dosing in infants and children 4 weeks of age and older<sup>a</sup>**

Drug	Strength of paediatric tablets or oral liquid	Number of tablets or MLS by weight-band morning (AM) and evening (PM)										Strength of adult tablet	Number of tablets by weight band	
		3-5.9 kg		6-9.9 kg		10-13.9 kg		14-19.9 kg		20-24.9 kg			25-34.9 kg	
		AM	PM	AM	PM	AM	PM	AM	PM	AM	PM		AM	PM
Solid formulations														
LPV/r <sup>b</sup>	Tablet 100 mg/25 mg	-	-	-	-	2	1	2	2	2	2	-	3	3
	Pellets 40 mg/10 mg	2	2	3	3	4	4	5	5	6	6	-	-	-
	Granules 40 mg/10 mg sachet	2	2	3	3	4	4	5	5	6	6	-	-	-

## References

- WHO updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, December 2018  
<https://apps.who.int/iris/bitstream/handle/10665/277395/WHO-CDS-HIV-18.51-eng.pdf>
- Annex 3: dosages for ARV drugs  
[https://www.who.int/hiv/pub/guidelines/ARV\\_Guidelines-2018-Annex3a.pdf](https://www.who.int/hiv/pub/guidelines/ARV_Guidelines-2018-Annex3a.pdf)
- WHO updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV, July 2018  
<https://apps.who.int/iris/bitstream/handle/10665/273632/WHO-CDS-HIV-18.18-eng.pdf>
- update of recommendations on first- and second-line antiretroviral regimens, July 2019 <https://www.who.int/hiv/pub/arv/arv-update-2019-policy/en/>



**World Health  
Organization**

International Committee of the Red Cross

International Federation of the Red Cross and Red Crescent Societies

Médecins Sans Frontières

United Nations Children's Fund

United Nations High Commissioner for Refugees

United Nations Population Fund

Addition to document  
ISBN 978-92-4-151522-1